Delaware’s PBM Disclosure Rules Clash: A National Precedent?

The unfolding dispute in Delaware regarding pharmacy benefit manager (PBM) disclosure rules highlights a burgeoning national trend towards greater transparency in prescription drug pricing. This state-level friction offers a crucial preview of how new federal PBM disclosure rules are poised to reshape the landscape for employer health plans nationwide.

At its core, this situation illuminates the increasing pressure on entities managing healthcare costs to reveal the mechanisms behind drug pricing—a development that stands to significantly empower benefits brokers and plan sponsors alike. Why has this issue suddenly gained such legislative traction?

Delaware’s Legislative Push for Transparency

A recent confrontation in Delaware has brought the opaque world of PBMs into sharp focus. Senator Ray Seigfried, a Democrat from Claymont and a former executive at ChristianaCare, has openly criticized the board overseeing health benefits for the state’s public employees. He alleges that the State Employee Benefits Committee has been sluggish in implementing essential drug-pricing reforms, despite clear legislative directives.

In 2025, Senator Seigfried sponsored a resolution specifically tasking this committee with exploring avenues to enhance transparency in PBM negotiations. The stakes are considerable, as the state’s Group Health Insurance Plan covers over 135,000 individuals, encompassing state employees, educators, law enforcement officers, retirees, and their families. Their access to affordable medication hinges on the effectiveness of these negotiations.

This legislative push reflects a broader sentiment that existing PBM practices often obscure the true costs and rebates associated with prescription drugs, potentially leaving plan sponsors and patients with higher expenses. Is this a localized concern, or does it echo a systemic challenge across the nation’s healthcare system?

Understanding Pharmacy Benefit Managers (PBMs)

Pharmacy Benefit Managers are pivotal, yet often misunderstood, intermediaries within the complex prescription drug supply chain. They manage prescription drug benefits for health insurers, Medicare Part D plans, large employers, and other plan sponsors. Their primary functions include negotiating drug prices with manufacturers, developing drug formularies—lists of covered drugs—and processing prescription claims.

Historically, PBMs have operated with a significant degree of confidentiality, citing proprietary business practices and competitive necessity. This opacity, however, has often led to questions regarding their revenue streams and whether cost savings are adequately passed on to plan sponsors and, ultimately, patients. Critics point to practices like spread pricing, where a PBM charges the health plan more for a drug than it reimburses the pharmacy, pocketing the difference.

Another contentious area involves manufacturer rebates. PBMs negotiate rebates from pharmaceutical companies in exchange for preferred formulary placement. The extent to which these rebates are shared with plan sponsors versus retained by the PBM has been a persistent source of friction. Are these arrangements truly benefiting the consumer, or primarily the intermediary?

The core challenge with PBM operations has always been a lack of granular insight into how value is distributed throughout the drug supply chain. Without clear disclosure, plan sponsors struggle to discern whether they are securing the best possible terms.

The calls for PBM disclosure rules aim to shed light on these financial flows, ensuring that plan sponsors have the necessary information to make informed decisions and truly evaluate the value offered by their PBM partners.

Federal Mandates and Industry Implications

The dispute in Delaware is not an isolated incident but rather a microcosm of a larger national movement. Congress has been actively rolling out similar transparency requirements for employer health plans, indicating a widespread recognition of the need for greater oversight of PBMs. These federal mandates are designed to empower employers by providing them with more comprehensive data on drug costs, rebates, and administrative fees.

Such federal PBM disclosure rules typically require PBMs to report detailed information to plan sponsors, including the total amounts paid to pharmacies, the aggregate rebates received, and any administrative fees or service charges. This unprecedented level of detail aims to eliminate the information asymmetry that has long favored PBMs in negotiations. What does this mean for the future of healthcare procurement?

For benefits brokers, these rules represent a significant opportunity to redefine their value proposition. Armed with enhanced data, brokers can conduct more thorough analyses of PBM contracts, identify potential inefficiencies or overcharges, and negotiate more aggressively on behalf of their clients. This shift promises to foster a more competitive environment, forcing PBMs to justify their pricing and demonstrate clear value.

Furthermore, these regulations may catalyze innovation within the PBM sector, encouraging new models that prioritize transparency and direct cost pass-through. The era of opaque, ‘black box’ pricing models for prescription drugs appears to be drawing to a close, ushering in a new age of accountability.

What Should You Do About PBM Disclosure Rules?

For employers and plan sponsors, the emergence of new PBM disclosure rules necessitates a proactive approach to managing prescription drug benefits. Simply accepting existing PBM contracts without scrutiny is no longer a viable strategy in this evolving regulatory environment. Vigilance and informed action are paramount.

• Scrutinize Existing Contracts: Review your current PBM agreements with an eye towards specific language regarding data sharing, reporting requirements, and the pass-through of rebates. Do these align with the spirit and letter of the new federal mandates?
• Demand Comprehensive Reporting: Actively request detailed reports from your PBM that outline drug costs, dispensed claims, actual rebates received, and any spread pricing applied. Utilize the leverage provided by new PBM disclosure rules to ensure full transparency.
• Engage Your Benefits Broker: Collaborate closely with your benefits broker. Their expertise in interpreting complex data and negotiating contracts will be invaluable in leveraging these new rules to your advantage, ensuring your plan achieves optimal savings and value.
• Explore Alternative Models: Consider alternative PBM models, such as transparent or pass-through PBMs, that openly disclose their revenue streams and commit to passing on all negotiated discounts to the plan. Is your current PBM truly competitive in this new landscape?

The regulatory shift signals a profound change in the balance of power, empowering plan sponsors with the information needed to drive more efficient and cost-effective prescription drug benefits. This proactive engagement will be critical in navigating the complexities of healthcare costs in the coming years.

Understanding PBM Disclosure Rules – Disclaimer

The information provided in this piece regarding PBM disclosure rules and their market implications is for informational purposes only. It does not constitute professional financial, legal, or healthcare advice. Market conditions and regulatory requirements are subject to change, and individual outcomes may vary significantly based on specific circumstances. Readers should consult with qualified financial advisors, legal counsel, or healthcare professionals to address their particular situations and make informed decisions.